Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

• DOI: 10.1172/jci81722
• Publication Date: 2015-08-14T13:48:27Z
• Authors: Mark R. Rigby; Kristina M. Harris; Ashley Pinckney; Linda A. DiMeglio; Marc S. Rendell; Eric I. Felner; Jean M. Dostou; Stephen E. Gitelman; Kurt J. Griffin; Eva Tsalikian; Peter A. Gottlieb; Carla J. Greenbaum; Nicole A. Sherry; Wayne V. Moore; Roshanak Monzavi; Steven M. Willi; Philip Raskin; Lynette Keyes-Els...; S. Alice Long; Sai Kanaparthi; Noha Lim; Deborah Phippard; Carol L. Soppe; Margret L. Fitzgi...; James McNamara; Gerald T. Nepom; Mario R. Ehlers
• Keywords: Clinical endpoint

BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes prolonged preservation endogenous insulin secretion remaining patients with newly diagnosed T1D.